Reaktionsgleichung
Cl[C:2]1[N:7]2[N:8]=[CH:9][CH:10]=[C:6]2[N:5]=[C:4]([NH:11][C:12](=[O:23])[C:13]2[CH:18]=[CH:17][C:16]([C:19]([OH:22])([CH3:21])[CH3:20])=[CH:15][CH:14]=2)[CH:3]=1.[N:24]1([CH:30]=[O:31])[CH2:29][CH2:28][NH:27][CH2:26][CH2:25]1>CN1C(=O)CCC1.CS(C)=O.CO>[CH:30]([N:24]1[CH2:29][CH2:28][N:27]([C:2]2[N:7]3[N:8]=[CH:9][CH:10]=[C:6]3[N:5]=[C:4]([NH:11][C:12](=[O:23])[C:13]3[CH:18]=[CH:17][C:16]([C:19]([OH:22])([CH3:21])[CH3:20])=[CH:15][CH:14]=3)[CH:3]=2)[CH2:26][CH2:25]1)=[O:31]Komponenten
6
Edukt 2
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 3
Versuchsvorschrift
A solution of N-(7-chloropyrazolo[1,5-a]pyrimidin-5-yl)-4-(2-hydroxypropan-2-yl)benzamide (2D, 50 mg, 0.151 mmol) and piperazine-1-carbaldehyde (34 mg, 0.302 mmol) in NMP (0.950 mL) was stirred at 85° C. overnight. After cooling to room temperature, the mixture was diluted with a few drops of DMSO and methanol, and was then purified by preparatory HPLC, 20-45% (MeCN/H2O gradient+0.01% TFA). Lyophilization of the combined fractions gave the titled compound as a white solid (35 mg, 57%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.45 (s, 6H) 3.59-3.82 (m, 8H) 6.39 (d, J=2.02 Hz, 1H) 7.43 (s, 1H) 7.60 (d, J=8.59 Hz, 2H) 8.00 (d, J=8.34 Hz, 2H) 8.08-8.15 (m, 2H) 10.94 (s, 1H). ESI-MS: m/z 409.2 (M+H)+.
Aufarbeitung
- customwas then purified by preparatory HPLC, 20-45% (MeCN/H2O gradient+0.01% TFA)
Quellen und Nachweise
- ORD-Eintrag
- ord-2a24bc410ea54c99b38c05457f28c6a2
- Quelldatensatz
- uspto-grants-2014_12
- Patentnummer
- US08921358B2
Verknüpfte Notizen
Wird geladen…